Novel aminopyrimidine egfr inhibitor

A compound represented by formula (I), a stereoisomer thereof, a tautomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, a solvate thereof or an isotope-labeled derivative thereof,

• wherein,
• R1 is selected from H, halogen, —CN, C1-6 alkyl, C1-6 heteroalkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, 3-6-membered heterocycloalkyl, C3-6 cycloalkyloxy, 3-6-membered heterocycloalkyloxy, and C2-6 alkenyloxy;
• M is selected from N or CR10;
• R10 and R1 may form a 5-8-membered heterocycloalkyl or a 5-7-membered heteroaryl;
• the 5-8-membered heterocycloalkyl and the 5-7-membered heteroaryl are optionally substituted by one or more R11 groups;
• R2 is selected from H, halogen, —CN, —OH, —NH2, phosphonyl, sulfonyl, aminosulfonyl, aminocarbonyl, carbonylamino, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-14 cycloalkyl, 3-14-membered heterocycloalkyl, C3-6 cycloalkenyl, C3-6 heterocycloalkenyl, phenyl and
• wherein, the —OH, —NH2, phosphonyl, sulfonyl, aminosulfonyl, aminocarbonyl, carbonylamino, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-14 cycloalkyl, 3-14-membered heterocycloalkyl, C3-6 cycloalkenyl, C3-6 heterocycloalkenyl, phenyl and
• are optionally substituted by one or more R12 groups;
• R3 is selected from —CN, sulfoximino, -L1-C6-10 aryl, -L1-5-12-membered heteroaryl, -L1-C3-6 cycloalkenyl and
• wherein, the —CN, sulfoximino, -L1-C6-10 aryl, -L1-5-12-membered heteroaryl, -L1-C3-6 cycloalkenyl and
• are optionally substituted by one or more R13 groups;
• L1 is independently selected from a linking bond, C1-4 alkyl and C1-4 heteroalkyl, wherein the C1-4 alkyl and C1-4 heteroalkyl are optionally substituted by one or more groups selected from —OH, —NH2 and halogen;
• R4 and R5 are each independently selected from H, halogen, —CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C3-8 cycloalkyl and 3-8-membered heterocycloalkyl;
• or, R4 and R5 are cyclized to 4-6-membered cycloalkyl, 4-6-membered heterocycloalkyl, 4-6-membered aryl or 4-6-membered heteroaryl;
• R6 is selected from amino, amido, aminocarbonyl, sulfonyl, thiophosphonyl, phosphonyl, phosphonoamino, sulfonylamino, aminosulfonyl and sulfoximino, wherein the amino, amido, aminocarbonyl, sulfonyl, thiophosphonyl, phosphonyl, phosphonoamino, sulfonylamino, aminosulfonyl and sulfoximino are optionally substituted by one or more R14 groups;
• R7, R8 and R9 are each independently selected from H, halogen, —CN, —OH, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, 3-6-membered heterocycloalkyl and 5-7-membered heteroaryl;
• or, R7 and R8 are cyclized to C4-6 cycloalkyl, 4-6-membered heterocycloalkyl, C5-6 aryl or 5-7-membered heteroaryl;
• or, R8 and R9 are cyclized to C4-6 cycloalkyl, 4-6-membered heterocycloalkyl, C5-6 aryl or 5-7-membered heteroaryl;
• R10 is selected from H, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and C1-6 haloalkoxy;
• R11 is selected from H, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, —C0-4 alkyl-NRaRb, —C1-4 alkyl-O—C1-4 alkyl, —C1-4 alkyl-OH, —O—C1-4 alkyl, —C0-4 alkyl-C3-6 cycloalkyl and —C0-4 alkyl-3-6-member heterocycloalkyl;
• R12 is selected from H, halogen, —CN, —OH, —NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-14-membered heterocycloalkyl, hydroxy-C1-6 alkyl-, C3-8 cycloalkylalkyl-, C3-8 cycloalkyloxy-, C3-8 heterocycloalkylalkyl-, C3-8 heterocycloalkyloxy-, C3-8 cycloalkyl-C1-6 alkoxy-, C3-8 heterocycloalkyl-C1-6 alkoxy-, C1-6 alkylsulfonyl, C3-6 cycloalkylsulfonyl, NRaRbCO—, C1-6 alkylcarbonyl, C3-8 cycloalkylcarbonyl, C1-6 alkoxy-C1-6 alkyl-, C3-6 cycloalkenyl, 5-12-membered heteroaryl, C6-10 aryl, NRaRbS(O)2—, —(CH2)mNRaRb, —(CH2)mO(CH2)nCH3 and —O(CH2)mNRaRb;
• wherein the Ra and Rb are independently H, C1-6 alkyl or C1-6 alkoxy, or the Ra and Rb together form a C3-8 cycloalkyl or 3-8-membered heterocycloalkyl;
• wherein the m and n are independently optionally 0, 1, 2 or 3, and the C3-8 cycloalkyl and 3-8-membered heterocycloalkyl are optionally substituted by a group selected from halogen, —OH, —NH2, —CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and —CO0-4 alkyl-O—C1-4 alkyl;
• R13 is selected from H, halogen, —CN, C1-6 alkyl, C1-6 heteroalkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3-8 cycloalkyl, 3-8-membered heterocycloalkyl, C3-6 cycloalkylsulfonyl, 5-6-membered heteroaryl and phenyl;
• R14 is selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C3-8 cycloalkyl and 3-8-membered heterocycloalkyl.